FAPI-46/双示踪剂PET/CT成像对食管癌放射治疗管理的影响
32例拟接受放化疗的食管癌患者行FDG与FAPI-46 PET/CT双示踪剂成像,比较功能肿瘤体积、大体肿瘤体积及分期。FAPI-46/双示踪剂PET/CT使5/32例(16%)放疗野增大、3/32例(6%)治疗方案改变,GTV较FDG-PET/CT更大(均值99.0 vs 80.3 ml,p<0.001)。
要点
- FAPI-46/双示踪剂PET/CT使5/32例(16%)放疗野增大(轻微改变),3/32例治疗方案改变(主要改变)。
- 联合FDG与FAPI-46 PET后12/32例(38%)淋巴结分期上调,2例淋巴结转移仅FAPI-46/双示踪剂可见。
- FAPI-46/双示踪剂PET/CT的GTV大于FDG-PET/CT(均值99.0 vs 80.3 ml,p<0.001)。
核心结论
- 首次报告FAPI-46 PET用于拟接受放疗的食管癌患者,肿瘤摄取高且不依赖肿瘤微环境中FAP表达。
- FAPI-46/双示踪剂PET在该背景下对治疗管理有相关影响,作者呼吁前瞻性评估以改善食管癌临床结局。
研究设计与样本
- 32例拟接受放化疗的食管癌患者,同日(双示踪剂方案,71%)或分两日(29%)行FDG与FAPI-46 PET/CT。
- 比较PET成像前后的功能肿瘤体积、大体肿瘤体积和肿瘤分期。
- 治疗改变分为「轻微」(调整放疗野)或「主要」(改变治疗方案)。
- 对所有有可用组织的患者行FAP免疫组化染色。
主要发现
- 原发肿瘤在所有FAPI-46/双示踪剂扫描中检出,在30/32(93%)FDG扫描中检出。
- 与初始分期CT相比,联合FDG与FAPI-46 PET后12/32例(38%)淋巴结分期上调。
- 2例淋巴结转移仅FAPI-46/双示踪剂可见,2/32例(6%)发现新远处转移。
- FAPI-46/双示踪剂PET/CT后5/32例(16%)放疗野增大(轻微改变),3/32例治疗方案改变(主要改变)。
- FAPI-46/双示踪剂扫描的GTV大于FDG-PET/CT(均值99.0 vs 80.3 ml,p<0.001),核医学FTV结果相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fibroblast activation protein (FAP) is expressed in the tumor microenvironment (TME) of various cancers. In our analysis, we describe the impact of dual-tracer imaging with Gallium-68-radiolabeled inhibitors of FAP (FAPI-46-PET/CT) and fluorodeoxy-D-glucose (FDG-PET/CT) on the radiotherapeutic management of primary esophageal cancer (EC). METHODS: 32 patients with EC, who are scheduled for chemoradiation, received FDG and FAPI-46 PET/CT on the same day (dual-tracer protocol, 71%) or on two separate days (29%) We compared functional tumor volumes (FTVs), gross tumor volumes (GTVs) and tumor stages before and after PET-imaging. Changes in treatment were categorized as "minor" (adaption of radiation field) or "major" (change of treatment regimen). Immunohistochemistry (IHC) staining for FAP was performed in all patients with available tissue. RESULTS: Primary tumor was detected in all FAPI-46/dual-tracer scans and in 30/32 (93%) of FDG scans. Compared to the initial staging CT scan, 12/32 patients (38%) were upstaged in nodal status after the combination of FDG and FAPI-46 PET scans. Two lymph node metastases were only visible in FAPI-46/dual-tracer. New distant metastasis was observed in 2/32 (6%) patients following FAPI-4 -PET/CT. Our findings led to larger RT fields ("minor change") in 5/32 patients (16%) and changed treatment regimen ("major change") in 3/32 patients after FAPI-46/dual-tracer PET/CT. GTVs were larger in FAPI-46/dual-tracer scans compared to FDG-PET/CT (mean 99.0 vs. 80.3 ml, respectively (p < 0.001)) with similar results for nuclear medical FTVs. IHC revealed heterogenous FAP-expression in all specimens (mean H-score: 36.3 (SD 24.6)) without correlation between FAP expression in IHC and FAPI tracer uptake in PET/CT. CONCLUSION: We report first data on the use of PET with FAPI-46 for patients with EC, who are scheduled to receive RT. Tumor uptake was high and not depending on FAP expression in TME. Further, FAPI-46/dual-tracer PET had relevant impact on management in this setting. Our data calls for prospective evaluation of FAPI-46/dual-tracer PET to improve clinical outcomes of EC.
引用
- Wegen S, Claus K, Linde P, et al. Impact of FAPI-46/dual-tracer PET/CT imaging on radiotherapeutic management in esophageal cancer. Radiat Oncol. 2024. PMID: 38575990. doi:10.1186/s13014-024-02430-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。